About Journey Medical Corp
Ticker
info
DERM
Trading on
info
NASDAQ
ISIN
info
US48115J1097
Industry
info
Drug Manufacturers - Specialty & Generic
Sector
info
Healthcare
CEO
info
Claude Maraoui
Headquarters
info
9237 East Via de Ventura Boulevard, Scottsdale, AZ, United States, 85258
Employees
info
41
Website
info
https://journeymedicalcorp.com
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Metrics
BasicAdvanced
Market cap
info
$209M
P/E ratio
info
-
EPS
info
-$0.35
Dividend Yield
info
0.00%
Beta
info
0.81
Forward P/E ratio
info
24.69
EBIDTA
info
$-1.3M
Ex dividend date
info
-
Price & volume
Market cap
info
$209M
Average daily volume
info
0.2M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
24.69
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
3.51
Price to book
info
7.76
Earnings
EPS
info
-$0.35
EPS estimate (current quarter)
info
-$0.04
EPS estimate (next quarter)
info
$0.05
EBITDA
info
$-1.3M
Revenues (TTM)
info
$59.4M
Revenues per share (TTM)
info
$2.58
Technicals
Beta
info
0.81
52-week High
info
$9.40
52-week Low
info
$3.54
50-day moving average
info
$7.75
200-day moving average
info
$7.01
Short ratio
info
9.85
Short %
info
14.99%
Management effectiveness
ROE (TTM)
info
-47.05%
ROA (TTM)
info
-4.60%
Profit margin
info
-14.58%
Gross profit margin
info
$39.2M
Operating margin
info
-8.67%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
20.50%
Share stats
Outstanding Shares
info
21.1M
Float
info
14.6M
Insiders %
info
31.39%
Institutions %
info
41.31%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 4 analysts.

Average price target

info
$13.50
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.10
-$0.17
157.97%
Q4 • 24Beat
-$0.18
-$0.24
24.21%
Q1 • 25Beat
-$0.16
-$0.11
-45.45%
Q2 • 25Missed
-$0.09
-$0.03
-200.00%
Q3 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$15M
$-3.8M
-25.29%
Q2 • 25
$17.6M
$-2.3M
-13.13%
Q3 • 25
17.47%
-39.01%
-48.08%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$81.2M
$61.9M
76.29%
Q2 • 25
$85.2M
$59.3M
69.60%
Q3 • 25
4.97%
-4.23%
-8.76%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-0.9M
-
$0.2M
$-0.9M
Q2 • 25
$-2.4M
-
$7M
$-2.4M
Q3 • 25
152.97%
-
4,165.45%
152.97%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Journey Medical Corp share?
Collapse

Journey Medical Corp shares are currently traded for undefined per share.

How many shares does Journey Medical Corp have?
Collapse

Journey Medical Corp currently has 21.1M shares.

Does Journey Medical Corp pay dividends?
Collapse

No, Journey Medical Corp doesn't pay dividends.

What is Journey Medical Corp 52 week high?
Collapse

Journey Medical Corp 52 week high is $9.40.

What is Journey Medical Corp 52 week low?
Collapse

Journey Medical Corp 52 week low is $3.54.

What is the 200-day moving average of Journey Medical Corp?
Collapse

Journey Medical Corp 200-day moving average is $7.01.

Who is Journey Medical Corp CEO?
Collapse

The CEO of Journey Medical Corp is Claude Maraoui.

How many employees Journey Medical Corp has?
Collapse

Journey Medical Corp has 41 employees.

What is the market cap of Journey Medical Corp?
Collapse

The market cap of Journey Medical Corp is $209M.

What is the P/E of Journey Medical Corp?
Collapse

The current P/E of Journey Medical Corp is null.

What is the EPS of Journey Medical Corp?
Collapse

The EPS of Journey Medical Corp is -$0.35.

What is the PEG Ratio of Journey Medical Corp?
Collapse

The PEG Ratio of Journey Medical Corp is null.

What do analysts say about Journey Medical Corp?
Collapse

According to the analysts Journey Medical Corp is considered a buy.